Delisting risk
Estrella Immunopharma (ESLA)
Develops ARTEMIS T-cell therapies for B-cell malignancies.
$0.6900
At close−0.00 (−0.22%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions16 holders · as of Mar 31, 2026 | 11.91% | 5.18M shares | |
| Insiders2 holders · as of Aug 26, 2026 | 1.79% | 779.6K shares | |
| Otherremainder | 86.30% | 37.54M shares |
43.50M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
16 holders · 5.18M shares · 8 new positions · 11 increased · 2 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.10M | 9.42% | +4.10Mnew | May 15, 2026 |
| Vanguard Capital Management LLC | 382.5K | 0.88% | +382.5Knew | May 15, 2026 |
| Wells Fargo & Company/MN | 264.4K | 0.61% | +264.4Knew | Jul 8, 2026 |
| Geode Capital Management, LLC | 157.5K | 0.36% | +47.7K | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 64.9K | 0.15% | +64.9Knew | May 8, 2026 |
| Renaissance Technologies LLC | 62.8K | 0.14% | −59.7K | May 14, 2026 |
| State Street Corp | 43.3K | 0.10% | 0 | May 15, 2026 |
| BlackRock, Inc. | 39.9K | 0.09% | +13.4K | May 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 4.28M | 13G | May 15, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 22, 2025 | Jiandong Xuofficer: Chief Financial Officer | Purchase | 1,000 | $1.16 | 16,700 |
| Sep 11, 2025 | Jiandong Xuofficer: Chief Financial Officer | Purchase | 100 | $1.04 | 264,588 |
| Oct 7, 2025 | Jiandong Xuofficer: Chief Financial Officer | Purchase | 1,000 | $1.33 | 265,488 |
CongressHouse and Senate disclosures
Not reported.
